Entrada Therapeutics Inc Quick Ratio (TRDA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Entrada Therapeutics Inc   (NASDAQ: TRDA)

Entrada Therapeutics Inc 's Quick Ratio

TRDA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Entrada Therapeutics Inc 's Cash & cash equivalent grew by 191.86 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Entrada Therapeutics Inc 's Quick Ratio to 10.44, above Entrada Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 100 other companies have achieved higher Quick Ratio than Entrada Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 950, from total ranking in the first quarter 2026 at 1179.

Explain Quick Ratio?
How much Cash & cash equivalents TRDA´s has?
What are TRDA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TRDA Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 7.92 % 4.15 % -38.07 % -65.98 % -76.92 %
Y / Y Cash & cash equivalent Change 207.82 % 12.69 % -10.69 % 19.52 % -60.87 %
Quick Ratio MRQ 10.44 3.98 3.7 3.88 3.66
TRDA's Total Ranking # 950 # 1179 # 1055 # 1120 # 1106
Seq. Current Liabilities Change 11.34 % -21.5 % 1.8 % 21.29 % 7.44 %
Seq. Cash & cash equivalent Change 191.86 % -15.43 % -3.1 % 28.7 % 6.85 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 101
Healthcare Sector # 152
Overall Market # 435


Quick Ratio Statistics
High Average Low
43.32 7.29 0.31
(Dec 31 2021)   (Sep 30 2023)




Financial Statements
Entrada Therapeutics Inc 's Current Liabilities $ 21 Millions Visit TRDA's Balance sheet
Entrada Therapeutics Inc 's Cash & cash equivalent $ 223 Millions Visit TRDA's Balance sheet
Source of TRDA's Sales Visit TRDA's Sales by Geography


Cumulative Entrada Therapeutics Inc 's Quick Ratio

TRDA's Quick Ratio for the trailling 12 Months

TRDA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -39.97 % -59.19 % -76.56 % -79.2 % -74.6 %
Y / Y Cash & cash equivalent TTM Growth 51.21 % -23.07 % -25.16 % -16.16 % -14.36 %
Quick Ratio TTM 5.43 3.8 3.74 3.29 2.15
Total Ranking TTM # 414 # 463 # 354 # 584 # 628
Seq. Current Liabilities TTM Growth 1.79 % 0.88 % -14.77 % -31.41 % -30.8 %
Seq. Cash & cash equivalent TTM Growth 45.29 % 2.66 % -3.23 % 4.77 % -26.08 %

Quick ratio ranking by company, industry and sector >> Back to TRDA Financial Strength Comparisons >> Go to Compare TRDA Quick Ratio to its Competitors

On the trailing twelve months basis TRDA Cash & cash equivalent more than doubled by 207.82 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Entrada Therapeutics Inc 's Quick Ratio to 5.43, above TRDA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Entrada Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2683.

Explain Quick Ratio?
How much Cash & cash equivalents TRDA´s has?
What are TRDA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 857
Within the Market # 950


trailing twelve months Quick Ratio Statistics
High Average Low
16.44 3.84 0.43
(Mar 31 2022)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions

Date modified: 2026-09-08T22:40:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.